Oculis (NASDAQ:OCS – Get Free Report) will post its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Oculis to post earnings of ($0.52) per share for the quarter.
Oculis (NASDAQ:OCS – Get Free Report) last released its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). The company had revenue of $0.27 million during the quarter, compared to analyst estimates of $0.28 million. Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. On average, analysts expect Oculis to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Oculis Stock Performance
Shares of Oculis stock traded down $0.27 during trading on Tuesday, reaching $17.32. The company’s stock had a trading volume of 69,048 shares, compared to its average volume of 36,184. The company has a current ratio of 5.27, a quick ratio of 5.27 and a debt-to-equity ratio of 0.01. The firm has a market cap of $701.46 million, a PE ratio of -9.02 and a beta of -0.16. Oculis has a fifty-two week low of $9.60 and a fifty-two week high of $18.00. The company has a 50-day moving average price of $13.62 and a two-hundred day moving average price of $12.47.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on Oculis
Oculis Company Profile
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Featured Articles
- Five stocks we like better than Oculis
- What is the Dow Jones Industrial Average (DJIA)?
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Insider Trades May Not Tell You What You Think
- Insider Buying Signals Upside for These 3 Stocks
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.